Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 9.7%

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Free Report)’s stock price rose 9.7% on Tuesday . The stock traded as high as $13.53 and last traded at $13.20. Approximately 459,229 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 863,216 shares. The stock had previously closed at $12.03.

Analyst Ratings Changes

DAWN has been the topic of several analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Finally, Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Check Out Our Latest Stock Report on DAWN

Day One Biopharmaceuticals Price Performance

The business’s 50-day moving average price is $14.70 and its two-hundred day moving average price is $14.70. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -5.33 and a beta of -1.53.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Free Report) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.05). As a group, sell-side analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.69 earnings per share for the current year.

Insider Transactions at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 52,183 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $17.89, for a total value of $933,553.87. Following the sale, the chief financial officer now directly owns 225,571 shares of the company’s stock, valued at $4,035,465.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,253 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total transaction of $52,308.24. Following the sale, the general counsel now directly owns 21,731 shares of the company’s stock, valued at $349,434.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Charles N. York II sold 52,183 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $17.89, for a total transaction of $933,553.87. Following the sale, the chief financial officer now directly owns 225,571 shares in the company, valued at $4,035,465.19. The disclosure for this sale can be found here. Over the last three months, insiders have sold 185,534 shares of company stock valued at $3,236,030. Corporate insiders own 8.40% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Quest Partners LLC bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter worth about $29,000. Quintet Private Bank Europe S.A. grew its position in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the last quarter. Amalgamated Bank grew its position in shares of Day One Biopharmaceuticals by 35.7% during the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after acquiring an additional 2,268 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Day One Biopharmaceuticals by 352.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock worth $147,000 after acquiring an additional 7,841 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in shares of Day One Biopharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after acquiring an additional 2,554 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

(Get Free Report)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

Read More

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.